Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
复制标题
DOI：
10.1159/000506976
复制
发表时间：
2020-01-01
影响因子：
0.8
通讯作者：
Aiba, Setsuya
中科院分区：
文献类型：
--
作者：
Kambayashi, Yumi;Fujimura, Taku;Aiba, Setsuya
免疫检查点抑制剂（ICIs）可显着延长转移性黑色素瘤患者的生存期，但可能导致严重的免疫相关不良事件。在本报告中，我们描述了一例在原发肿瘤切除前由纳武单抗加伊匹单抗联合治疗引起的非典型神经病变的病例。在我们的病例中，不仅出现脱髓鞘性神经病变，还出现肌肉无力和单侧面神经麻痹，并表现为严重而多样的症状。此外，与自发发生的脱髓鞘性周围神经病不同，本病例表明高剂量甲基强的松龙单药疗法对 ICI 诱导的免疫相关性脱髓鞘性周围神经病的治疗效果良好。
Immune checkpoint inhibitors (ICIs) significantly prolong survival in patients with metastatic melanoma but can lead to serious immune-related adverse events. In this report, we described a case of atypical neuropathy caused by nivolumab plus ipilimumab combination therapy before primary tumor resection. In our case, not only demyelinating neuropathy, but also muscle weakness and unilateral facial nerve palsy developed and manifested as severe and diverse symptoms. Moreover, unlike spontaneously developing demyelinating peripheral neuropathy, the present case suggested the therapeutic effects of high-dose methylprednisolone monotherapy for the treatment of ICIs-induced immune-related demyelinating peripheral neuropathy.